ACTRN12611000765921招募中2 期
A placebo controlled trial of methylphenidate for treatment of cognitive and behavioural impairment in children and adolescents with neurofibromatosis type 1.
The Children's Hospital at Westmead0 个研究点目标入组 36 人开始时间: 2011年7月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 7 Years 至 16 Years（—）
- 性别
- All
入选标准
- •1. All participants must fulfil the diagnosis of NF1 based on NIH criteria (NIH, 2000);
- •2. Participants must have a full scale IQ greater than or equal to 70 or if a significant discrepancy is present between PRI and VCI the higher will be used. This index used must be 70 or above;
- •3. Participants’ behaviour must be rated as abnormal by their parent on the Conners 3. An abnormal score is defined as a T score equal to or greater than 65 on the following scales inattention, hyperactivity/impulsivity.
- •4. Participants must have a cognitive impairment defined as having a score of at least one standard deviation or more below the population mean on at least one of the primary objective outcome measures:
- •a) Conner’s Continuous Performance Test –II (CPT II Omissions)
- •b) CANTAB Spatial Working Memory (SWM) (between errors total).
排除标准
- •1. Participants who have intracranial pathology such as epilepsy, hydrocephalus, diagnosed traumatic brain injury, or progressive intracranial tumours (children with asymptomatic or static lesions will be eligible);
- •2. Children who have significant visual and/or hearing problems;
- •3. Children who have contraindications to stimulant medication. These include those with glaucoma, hypertension, previous insensitivity to stimulant medication or are on contraindicated medication such as monoamine oxidase (MAO) inhibitors;
- •4. Children with Tourette’s syndrome, tics, or other major psychiatric disorders;
- •5. Female participants of childbearing age should not be pregnant, must have a negative urine pregnancy test before initiation of treatment;
- •6. Children who have received any investigational drugs of any type within 30 days of initiation of study;
- •7. Children with a co-existing medical condition that is likely to interfere or who are taking any concomitant medication that is likely to interfere with safe administration of methylphenidate in the investigators opinion.
- •8. Children who are requiring any of the following medications: clonidine or other alpha2 adrenergic receptor agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors, theophylline, coumarin, or anticonvulsants.
- •9. Children who have blood pressure measurements (systolic or diastolic) equal to or greater than 95th percentile for age, sex and height at screening.
- •10. Children who require drug therapy or hospitalisation for treatment of a mood disorder or anxiety disorder.
- •11. Children with ECG abnormalities that are deemed clinically significant
- •12. Children with drug or alcohol abuse or dependence within the prior six months
- •13. Children who are currently on stimulant medication for ADHD before the trial will be required to undergo a 3 week washout period prior to the screening assessment to minimise any potential carry over effects of the drug and allow the parents and teachers to complete the behavioural questionnaire based on the child's off medication behaviour.
研究者
相似试验
招募中
3 期
Effectiveness of psychostimulant and broader action antidepressant medications for patients with melancholic depressioMelancholic DepressionMental Health - DepressionACTRN12613000209796niversity of New South Wales225
招募中
2 期
Effect of 3, 4-Methylenedioxymethamphetamine (MDMA)-assisted therapy on Mood and Anxiety symptoms in patients with advanced-stage Cancer Study (EMMAC Study)ACTRN12619001334190niversity of Otago32
已完成
不适用
Clinical trial of long acting methylphenidate in amphetamine addicts with Attention Deficit Hyperactivity Disorder (ADHD)Attention deficit hyperactivity disorderMental and Behavioural DisordersISRCTN81602628Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)24
进行中（未招募）
不适用
Clinical trial of sustained release methylphenidate for Attention-Deficit-Hyperactivity-Disorder (ADHD) in adult criminal offenders with amphetamine addictio54 male prison inmates (27 in each treatment condition) that meet the DSM-IV criteria for amphetamine addiction and for ADHD and who are servicing their prison sentence are recruited.EUCTR2006-002249-35-SEAddiction Center Stockholm54
已完成
不适用
Clinical trial of sustained release methylphenidate for Attention Deficit Hyperactivity Disorder (ADHD) in adult criminal offenders with amphetamine addictioISRCTN77940178Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)54